Developing drugs with highly specific activity and reduced risk of off-target effects.
Dimerix is a privately held drug discovery company developing a pipeline of lead compounds with highly specific activity and reduced risk of off-target effects to treat diseases in oncology, metabolic disorders, cardiovascular and inflammation.
Dimerix’ unique G-Protein Coupled Receptor Heteromer Identification Technology (GPCR-HIT) platform includes a library of novel GPCR heteromer targets, screening and profiling capabilities and knowledge of biased intracellular signalling mediated through GPCR heteromers.
This platform enables Dimerix to identify and develop the best lead compounds that target GPCR heteromers.
View a brief profile on Dimerix Bioscience and our GPCR-HIT platform:
The Hon Mark Butler MP presents A/Prof. Kevin Pfleger with an NHMRC award for the ‘Ten of the Best’ research 2010 in the courtyard adjacent to the House of Representatives Chamber, Parliament House Canberra on 9 February 2011.